Local recurrence‐free survival · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
It is very uncertain whether skin‐sparing mastectomy changes local recurrence‐free survival compared with conventional mastectomy (very low certainty).
1 finding from 1 review
HR 0.82 [0.47, 1.42]
5690 participants
Very low
Overall complications,assessed using the number of participants with at least one local or systemic complication · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
It is very uncertain whether skin‐sparing mastectomy changes overall complications,assessed using the number of participants with… compared with conventional mastectomy (very low certainty).
1 finding from 1 review
RR 1.55 [0.97, 2.46]
677 participants
Very low
Breast reconstruction loss · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
It is very uncertain whether skin‐sparing mastectomy changes breast reconstruction loss compared with conventional mastectomy (very low certainty).
1 finding from 1 review
RR 1.79 [0.31, 10.35]
475 participants
Very low
Skin necrosis · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
It is very uncertain whether skin‐sparing mastectomy changes skin necrosis compared with conventional mastectomy (very low certainty).
1 finding from 1 review
RR 1.15 [0.62, 2.12]
677 participants
Very low
Infection · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
It is very uncertain whether skin‐sparing mastectomy changes infection compared with conventional mastectomy (very low certainty).
1 finding from 1 review
RR 2.04 [0.03, 142.71]
371 participants
Very low
Hemorrhage · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
It is very uncertain whether skin‐sparing mastectomy changes hemorrhage compared with conventional mastectomy (very low certainty).
1 finding from 1 review
RR 1.23 [0.47, 3.27]
677 participants
Very low
Vision‐related patient‐reported outcome measurement at 6 months (the greater the score, the better) · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
1 finding from 1 review
Clinical measures, such as reading speed or reading acuity at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Compliance · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Technical difficulties · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
It is very uncertain whether telerehabilitation changes technical difficulties with the intervention at 6 months compared with self‐training (very low certainty).
1 finding from 1 review
Device abandonment rate at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
It is very uncertain whether telerehabilitation changes device abandonment rate at 6 months compared with self‐training (very low certainty).
1 finding from 1 review
Surgical field bleeding score (during surgery or < 30 minutes after surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps
1 finding from 1 review
Intraoperative blood loss (mL) · adults and children with chronic rhinosinusitis with or without nasal polyps
1 finding from 1 review
Significant adverse events (seizures, thromboembolism) within 24 hours of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in significant adverse events (seizures, thromboembolism) within 24… compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Duration of surgery (minutes) Assessed as: total surgical time · adults and children with chronic rhinosinusitis with or without nasal polyps
1 finding from 1 review
Incomplete surgery · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in incomplete surgery compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Overall rate of surgical complications · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in surgical complications compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Postoperative bleeding (place of packing or revision surgery within 14 days of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in postoperative bleeding (place of packing or revision surgery within… compared with placebo (saline solution or sterile water) (low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with hair growth stimulants (minoxidil) (very low certainty).
1 finding from 1 review
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found